Does Rasonque Really Double Pancreatic Cancer Survival?

For twenty years, second-line treatment for metastatic pancreatic cancer has meant roughly six months of life on toxic combination chemotherapy. Rasonque is the first drug in this setting to substantially extend that, and it does it by hitting the mutation nearly every pancreatic tumor is built on.

The trial that broke the six-month ceiling

About 92% carried a RAS G12 mutation, the population where survival endpoints were prespecified. In that group, the pill produced a median overall survival of 13.2 months versus 6.6 months with chemo. Time before the cancer progressed went from 3.5 months to 7.3.

The share of patients who had to stop treatment for side effects fell from about 11% on chemo to about 1% on the pill. That last number matters. It's a drug you can stay on. The chemo arm's numbers tracked with what standard second-line therapy has delivered for years, so this is a fair comparison to today's care, not a straw man.

Why almost every patient qualifies

KRAS is mutated in about 90% of pancreatic tumors and is what drives them to grow. The two earlier KRAS drugs on the market, sotorasib and adagrasib, target only one variant called G12C, which shows up in just 1 to 2% of pancreatic cancers. So almost no one with the disease could take them.

Daraxonrasib works differently. It grabs an abundant helper protein inside the cell, and the combined complex physically blocks active mutant RAS from signaling. Because the blockade doesn't depend on the shape of any one mutation, the drug hits all four major codon-12 variants at once: G12D, G12V, G12R, and G12C. Together those account for essentially all KRAS-mutant pancreatic cancer. The FDA label reflects this. No companion mutation test is required to start. If you have metastatic pancreatic adenocarcinoma and have progressed on chemo, or you can't tolerate combination chemo, you're eligible.

Rash, resistance, and $39,800 a month

The drug is oral and outpatient, but it isn't gentle. In the trial, about 86% of patients had some skin toxicity, 63% had diarrhea, and 57% developed mouth sores. Most of that was mild to moderate and manageable, which is why so few patients stopped. Rare serious risks the label flags include interstitial lung disease in about 2 in 100. New belly pain or shortness of breath while on the drug is a reason to be seen quickly.

Resistance is the other limit. Cancers typically find their way around the drug before a year is out, and preclinical work has already mapped the escape routes. This is not a cure.

The U.S. list price is $39,800 for a 30-day supply. The manufacturer runs a co-pay program that may zero out the cost for eligible commercially insured patients, but real out-of-pocket burden will vary widely by insurance.

What comes next

For a disease where progress has been measured in weeks, doubling second-line survival is the kind of result the field has waited a generation to see. If you or someone you love has metastatic pancreatic cancer and has progressed on first-line chemotherapy, this is worth raising with the oncologist now. The strongest evidence is in patients still up and about most of the day. A mutation test isn't required to start the drug, but full molecular profiling of the tumor is still worth doing to shape the rest of the plan.

A few things will tell us how far this really goes: longer follow-up to see whether the tail of the survival curve produces true long-term responders or only delays the same ending, head-to-head data against NALIRIFOX, and real-world outcomes in older, sicker patients who weren't in the trial. For now, this is the first crack in a wall that stood for two decades.